

AD _____

Award Number: DAMD17-01-1-0056

TITLE: Hierarchical Nonlinear Mixed Effect Modeling: Defining
Post-Radiation Therapy Relapse in Prostate Cancer
Patients

PRINCIPAL INVESTIGATOR: Alexandra L. Hanlon, Ph.D.

CONTRACTING ORGANIZATION: Fox Chase Cancer Center
Philadelphia, Pennsylvania 19111

REPORT DATE: July 2002

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20030509 183

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)**2. REPORT DATE**
October 2002**3. REPORT TYPE AND DATES COVERED**
Annual (1 July 01 - 30 June 02)**4. TITLE AND SUBTITLE**

Hierarchical Nonlinear Mixed Effect Modeling: Defining Post-Radiation Therapy Relapse in Prostate Cancer Patients

5. FUNDING NUMBER

DAMD17-01-1-0056

6. AUTHOR(S)

Alexandra L. Hanlon, Ph.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)Fox Chase Cancer Center
Philadelphia, Pennsylvania 19111**E-Mail:** al_hanlon@fccc.edu**8. PERFORMING ORGANIZATION REPORT NUMBER****9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)**U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012**10. SPONSORING / MONITORING AGENCY REPORT NUMBER****11. SUPPLEMENTARY NOTES****12a. DISTRIBUTION / AVAILABILITY STATEMENT**

Approved for Public Release; Distribution Unlimited

12b. DISTRIBUTION CODE**13. ABSTRACT (Maximum 200 Words)**

During this grant period, a linear-quadratic random effects model of the profile of PSA levels in men following radiation therapy for prostate cancer was developed. It can be used to predict, for a new patient, the expected trajectory of future PSA levels, and the probability of biochemical failure. The model, which includes terms for initial PSA, post-treatment PSA nadir, time of nadir, and future PSA level, also allows us to update these predictions as new PSA measurements on the patient are collected. We show that our method has some advantages over the widely used definition of biochemical failure as three consecutive rises in post-nadir PSA level.

14. SUBJECT TERMS

prostate cancer

15. NUMBER OF PAGES

8

16. PRICE CODE**17. SECURITY CLASSIFICATION OF REPORT**

Unclassified

18. SECURITY CLASSIFICATION OF THIS PAGE

Unclassified

19. SECURITY CLASSIFICATION OF ABSTRACT

Unclassified

20. LIMITATION OF ABSTRACT

Unlimited

Table of Contents

Cover	1
SF 298	2
Introduction	4
Body	5
Key Research Accomplishments.....	5
Reportable Outcomes	6
Conclusions	6
References	7
Bibliography of Publications.....	8
List of Personnel.....	8
Appendices	8

Introduction

The public abstract in the original grant proposal reads as follows:

The definition of disease relapse following definitive radiation therapy for localized prostate cancer is a critical issue in the initial selection of salvage therapy as well as in the identification of patients in whom adjuvant therapy may be necessary. In September 1996, a panel of clinicians agreed on a definition of biochemical failure based on three consecutive rises in serial post-therapy serum prostatic antigen levels (Cox et al, 1997). The validity of the consensus definition has been questioned since its inception, leading to confusion and anxiety for patients as well as their physicians (Taylor et al, 2001).

The principal investigator of the proposed research developed a model to classify prostate cancer patients according to disease relapse following definitive radiation therapy (Hanlon, 1998). The model was developed and tested statistically using a subset of 35 patients with relatively homogenous tumor and treatment characteristics: men presenting with pretreatment PSA levels between 10 and 19.9 ng/mL and treated with three dimensional conformal radiation therapy. In order to evaluate the clinical utility of the model, we propose to apply it to a much larger population of men that represent all stages of presenting disease. The specific aim of the proposed research is to validate our classification model by applying it to an existent database of 261 prostate cancer patients via the modeling of covariates, including tumor differentiation as defined by Gleason Score, palpation tumor stage, and pre-treatment PSA. We propose an analysis of predictors of post-nadir rise, as salvage therapy strategies are often designed around the rate of increase in PSA levels post-nadir. Similarly, we propose an analysis of predictors of initial decline and its relationship to outcome, as this may be useful in defining early intervention strategies for relapse. The validity of the modeling will be assessed by comparing biochemical classification to clinical results as obtained from biopsy. An analysis will be performed to assess the time it takes to acceptably stratify patients according to post-treatment disease status.

The proposed research will provide insight into the much-debated issue of prostate cancer "relapse". Such insight could have tremendous implications in defining treatment strategies for salvage therapy. It has advantages over the much-disputed

clinical classification, including the lack of clinical bias, noise insensitivity, and the ability to predict treatment failure at earlier points in time. The proposed research also has relevance in the area of quality of life, as the debate over relapse is the source of significant anxiety for both patients and treating physicians.

The following progress report represents a summary of work accomplished during the period 01 July 2001 through 04 February 2002. *The Principal Investigator, Dr. Alexandra Hanlon, resigned from her position at Fox Chase Cancer Center effective 04 February 2002 and thus this report is also the Final Progress Report for this award.*

Body

Within the department of Radiation Oncology at Fox Chase Cancer Center, 533 men were treated between 4/89 and 12/99 for prostate cancer and were the basis of a training set for a linear-quadratic random effects model. The patients had a mean of 11.9 PSA observations each. A quadratic-linear spline model with non-linear random effects was fitted to the 533 observed PSA profiles (Davidian and Giltinan, 1995). To evaluate the predictive ability of the model, the following procedure was used: for each subject in turn, a prediction of time of biochemical failure was made using each of two definitions. One definition, which is widely used in clinical practice, is three consecutive rises in post-nadir PSA levels. The other definition, which is derived from the spline model, is a rise of a specified amount of the post-nadir predicted PSA level.

Key Research Accomplishments

- A linear-quadratic random effects model of the profile of PSA levels in men following radiation therapy for prostate cancer was developed. The model can be used to predict, for a new patient, the expected trajectory of future PSA levels, and the probability of biochemical failure. The model, which includes terms for initial PSA, post-treatment PSA nadir, time of nadir, and future PSA level, also allows for updated predictions as new PSA measurements at the patient level are collected.


Reportable Outcomes

Thirty-three percent (78/533) of the subjects experienced biochemical failure as defined by three successive rises in post-nadir PSA, and 31% (167/533) of the subjects experienced a rise of 1.8 units of log PSA levels in 5 years following PSA nadir. The critical value of 1.8 units was chosen to make the model-based predicted failure rate comparable to that produced by the “three successive rises” method. The two prediction methods produced the same prediction in 444/533 subjects (83%) and produced opposing predictions in the remaining 17% of subjects. In the 128 cases when both methods predicted biochemical failure, the model-based method predicted it earlier in 66 subjects, while the “three rises” method predicted it earlier in just 20 subjects. Both methods predicted failure at the same time in 42 subjects.

Conclusions

Our database of the PSA profiles of 533 patients may be used as a training set to develop a predictive model for the future PSA trajectory for a new patient, and the prediction may be updated as new PSA information is acquired. A critical value may be defined in terms of a predicted rise of 1.8 units of log PSA level over 5 years, yielding a predicted biochemical failure rate of 31%. The “three successive rises” method has two important disadvantages when compared to the spline model prediction method: a slow but steady increase in post-nadir PSA levels will be classified as a failure under the “three rises” method, but may not signify a clinically meaningful rise within a patient’s expected lifetime; and a patient with highly variable post-nadir PSA levels may experience a clinically significant rate of increase in PSA levels, but never experience three significant rises. For example, Figure 1 presents a patient with clear biochemical failure, as shown by the predicted profile (solid line), but there are never three consecutive rises in the PSA levels. Model-based prediction methods such as the one presented here hold promise as enhanced tools for predicting biochemical failure.

Fig. 1. Patient with biochemical failure without three successive rises



References

- Cox, J., Grignon, D., Kaplan, R., Parsons, J., Schellhammer, P. (1997), "Consensus Statement: Guidelines for PSA Following RT," *International Journal Radiation Oncology, Biology, Physics*, 37,1035-1041.
- Davidian, M., and Giltinan, D. M. (1995), *Nonlinear Models for Repeated Measurement Data*, London: Chapman and Hall.
- Hanlon, A. (1998), "Hierarchical Nonlinear Mixed Effects Modeling: Inference and Classification Using a Fully Parametric Model", unpublished Ph.D. dissertation, Temple University.
- Taylor, J.M., Griffith, K.A., Sandler, H.M. (2001), "Definitions of Biochemical Failure in Prostate Cancer Following Radiation Therapy," *International Journal Radiation Oncology, Biology, Physics*, 50,1212-1219.

Bibliography of Publications

None to date

List of Personnel

Alexandra Hanlon

Appendices

None